Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Capital Expenditures: 2018-2025

Historic Capital Expenditures for UroGen Pharma (URGN) over the last 8 years, with Sep 2025 value amounting to $87,000.

  • UroGen Pharma's Capital Expenditures fell 9.38% to $87,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $387,000, marking a year-over-year increase of 15.18%. This contributed to the annual value of $295,000 for FY2024, which is 52.06% up from last year.
  • Latest data reveals that UroGen Pharma reported Capital Expenditures of $87,000 as of Q3 2025, which was down 38.30% from $141,000 recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Capital Expenditures peaked at $287,000 during Q1 2021, and registered a low of $13,000 during Q4 2022.
  • For the 3-year period, UroGen Pharma's Capital Expenditures averaged around $76,100, with its median value being $85,500 (2024).
  • As far as peak fluctuations go, UroGen Pharma's Capital Expenditures crashed by 93.56% in 2022, and later skyrocketed by 460.00% in 2024.
  • Quarterly analysis of 5 years shows UroGen Pharma's Capital Expenditures stood at $202,000 in 2021, then crashed by 93.56% to $13,000 in 2022, then soared by 330.77% to $56,000 in 2023, then surged by 105.36% to $115,000 in 2024, then decreased by 9.38% to $87,000 in 2025.
  • Its Capital Expenditures stands at $87,000 for Q3 2025, versus $141,000 for Q2 2025 and $44,000 for Q1 2025.